- Report
- January 2024
- 200 Pages
Global
From €4796EUR$5,000USD£4,120GBP
- Report
- February 2024
- 175 Pages
Global
From €4796EUR$5,000USD£4,120GBP
- Report
- February 2024
- 175 Pages
Global
From €4796EUR$5,000USD£4,120GBP
- Report
- November 2023
- 30 Pages
Global
From €2638EUR$2,750USD£2,266GBP
- Report
- July 2022
- 150 Pages
Global
From €5708EUR$5,950USD£4,903GBP
- Report
- June 2020
- 114 Pages
Global
From €4557EUR$4,750USD£3,914GBP
- Report
- August 2023
- 389 Pages
Global
From €3425EUR$3,570USD£2,942GBP
- Book
- April 2019
- 288 Pages
- Book
- October 2019
- 720 Pages
- Book
- November 2011
- 224 Pages
Glycopeptides are a class of antibiotics used to treat serious bacterial infections. They are derived from a polysaccharide-peptide backbone and are effective against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Glycopeptides are typically used in combination with other antibiotics to treat infections that are resistant to other antibiotics. They are also used to prevent infections in patients who are immunocompromised or undergoing surgery.
Glycopeptides are generally more expensive than other antibiotics, and their use is limited due to their narrow spectrum of activity. However, they are an important part of the antibiotic arsenal and are used in cases where other antibiotics are ineffective.
Some companies in the glycopeptides market include Merck, Pfizer, AstraZeneca, and GlaxoSmithKline. Show Less Read more